Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of rilonacept for prophylaxis of gout flares in patients on urate-lowering therapy
2008-007784-16Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute gout flare and gout comparing Rilonacept 160 mg SC with Placebo SC (2 arms). Primary endpoint: Safety and tolerability of rilonacept. Started Mar 2009; status: completed.
02
Drugs
rilonacept
03
Conditions
acute gout flaregout
Beyond the preview
Go deeper on 2008-007784-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007784-16.